Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. reports developments tied to its transition toward AI-powered scent intelligence and industrial sensing. The company centers its commercial focus on AI Nose, an electronic olfaction platform that uses sensor arrays and proprietary artificial intelligence models, including its Smell Language Model, to convert volatile organic compound and scent signals into machine-readable Smell ID data.
Recurring news themes include AI Nose commercialization across semiconductor manufacturing, robotics, smart infrastructure, and healthcare-related environments; distribution and deployment relationships; industry classification updates; and financial results connected to the platform. Ainos also maintains a therapeutic-development program around VELDONA, a low-dose oral interferon program targeting rare, autoimmune, and infectious diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ainos, a diversified medtech company, reported a remarkable 3,832% year-over-year increase in revenues, reaching US$1,038,025 in Q4 2022. The gross profit also surged by 2,668% to US$459,815, yielding a gross margin of 44.3%. For the full year, revenues increased 492% to US$3,519,627 driven by strong sales of COVID-19 antigen self-test kits. However, the company incurred a net loss of US$14,006,690 for 2022. Ainos signed MoUs with partners to expand its VELDONA® product line and secured US$3 million in a convertible note placement, enhancing its capital base for further development.